Takeda secures a fast review for new cancer drug; ReGenX eyes $121M in gene therapy IPO;

@FierceBiotech: Penn scientists identify viral products that defend against respiratory syncytial virus. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Who you going to buy? Gilead banks $10B, stirring fresh buzz about a blockbuster buyout. Article | Follow @JohnCFierce

@DamianFierce: Flemming Ornskov, "avid postcard and letter writer" who keeps up on household chores. More | Follow @DamianFierce

> Takeda won the FDA's priority review designation for the multiple myeloma treatment ixazomib, guaranteeing a 6-month review time for the drug instead of the usual 10-month process. More

> Third Rock Ventures give Bloomberg a post-mortem on Ember Therapeutics, a once-promising biotech startup whose bet on a new treatment for obesity came up short. Story

> Gene therapy pioneer ReGenXBio updated the terms of its planned IPO, seeking up to $121.4 million to support its pipeline of rare disease treatments. News

Medical Device News

@FierceMedDev: Biogen CEO says the biotech aims to develop wearable and ingestible devices. More | Follow @FierceMedDev

@VarunSaxena2: Robotic surgery aspirant receives $4M+ in equity financing. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Roche CEO: Despite China worries, emerging markets will continue to deliver growth. Article | Follow @EmilyWFierce

> JAMA: Women face increased risk for second vaginal mesh surgery 10 years after implant. More

> Delphinus raises $39M+ to back pivotal trial of more effective dense breast tissue ultrasound imaging. Article

Pharma News

@FiercePharma: ICYMI yesterday: Ireland plant with 100 workers on Sun's list for sale or closure. Item | Follow @FiercePharma

@EricPFierce: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Icahn casts his eye on Vivus with tender offer for convertible notes. More | Follow @CarlyHFierce

> Study: Patients sticking to their scripts saved Medicaid money. More

> Bernie Sanders unveils bill to battle rising drug prices. Article

Vaccines News

> UC Berkeley scientists identify protein that causes dengue shock as a potential vaccine target. Item

> With limited ACIP nod, U.S. universities take different approaches to Pfizer, GSK MenB jabs. Report

> VBI Vaccines scores up to $265,000 from Canadian organization for RSV vaccine. Story

> Analysis: Sanofi's Fluzone High Dose for adults 65+ results in lower medical costs. Article

> Merck's Zostavax not cost-effective for those in their 50s: Study. More

CRO News

> Aragen licenses a protein technology to speed up biologics R&D. Item

> Rho snags a $120M federal contract with NIH. Story

> Recipharm signs on to make LobSor's Parkinson's drug as it negotiates with Novartis. Article

> Icon teams up with IBM to accelerate clinical trial startup. News

> Surging dollar blunts Catalent's revenue, but profits soar in fiscal '15. Article

Pharma Manufacturing News

> Bangladesh-based Square Pharmaceuticals has two new plants online. Item

> Canada allows Apotex Indian plants to regain access to its markets. More

> GSK recalls more than 425K tubes of antibiotic cream. Report

> Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. Article

> Glaxo starts $153M plant in India. Story

Pharma Asia News

> Japan's Takeda gets U.S. FDA priority review for ixazomib. Item

> FT counts 39 plants banned in India as regulatory woes mount for drugmakers. More

> China Daily carries lengthy industry-linked op-ed against overuse of stents. Report

> Apotex sees Health Canada lift ban on two India plants. Story

> Chugai and Roche get U.S. FDA priority review on alectinib. Article

Suggested Articles

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.

Durect's treatment lowered scores that reflect the likelihood a person with alcoholic hepatitis will die within a certain period of time.